MyOvarianCancerTeam

What are the survival rates for relapsed high-grade serous carcinoma (HGSC)?

For HGSC overall, the median survival is about 3.3 years after initial diagnosis, meaning half of people live longer and half live less time. However, outcomes vary widely based on individual factors.

When HGSC relapses, which happens in most cases Show Full Answer

What are the survival rates for relapsed high-grade serous carcinoma (HGSC)?

For HGSC overall, the median survival is about 3.3 years after initial diagnosis, meaning half of people live longer and half live less time. However, outcomes vary widely based on individual factors.

When HGSC relapses, which happens in most cases (often within three years), survival depends on several factors:

* Cancer stage at relapse
* How well the cancer responds to treatment
* Time between initial treatment and relapse
* Overall health and age

For all stages of invasive epithelial ovarian cancer combined:
* Localized cancer: 92% five-year survival rate
* Regional spread: 71% five-year survival rate
* Distant metastasis: 32% five-year survival rate

The treatment you're receiving (bevacizumab with liposomal doxorubicin and carboplatin) is a standard approach for relapsed ovarian cancer. Bevacizumab is an angiogenesis inhibitor that blocks blood supply to tumors.

Unfortunately, specific survival data for India isn't available in the research, but these rates generally apply across populations. Your oncologist can provide more personalized information based on your specific situation, including how your cancer is responding to current treatment and your CA125 trends.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

High-Grade Serous Carcinoma: Prognosis, Management, and More